Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study of Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Prior Adjuvant Therapy With CDK4/6 Inhibitors

NCT05806047 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05806047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05806047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study of Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Prior Adjuvant Therapy With CDK4/6 Inhibitors
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Unknown status
Start date
May 1, 2023
Completion date
November 1, 2024
Enrollment
23 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hormone receptor-positive advanced breast cancer